YP1A Stock Chart & Stats
€0.31
<€0.01(0.63%)
At close: 4:00 PM EDT
€0.31
<€0.01(0.63%)
Day’s Range― - ―
52-Week Range€0.24 - €2.92
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€42.77M
Enterprise Value€14.45
Total Cash (Recent Filing)€68.88M
Total Debt (Recent Filing)€1.05M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Feb 25, 2027EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding147,372,130
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.44
Price to Sales (P/S)6.23
P/FCF Ratio-1.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.30Price Target Upside319.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.09
Revenue Forecast (FY)€2.34M
Bulls Say, Bears Say
Bulls Say
Licensing-driven Revenue GrowthThe new licensing revenue demonstrates that Immutep can monetize its LAG-3 assets through strategic partnerships before product commercialization. This provides business-development validation and creates potential for future milestone, collaboration, or royalty income as partnered programs advance.
Improved Gross ProfitabilityThe sharp gross-margin rebound indicates that the company’s improving revenue mix or reduced cost distortions can support better economics on recognized revenue. If sustained through additional partnering activity, this could increase the portion of revenue available to fund ongoing clinical development.
Low Financial LeverageMinimal debt limits solvency pressure and reduces the burden of interest and refinancing obligations while Immutep funds clinical programs. This gives management greater flexibility to allocate available capital toward research, partnerships, and development rather than debt servicing.
Bears Say
Large And Widening LossesThe widening loss shows that emerging licensing revenue has not yet offset Immutep’s development and corporate cost base. Persistent unprofitability limits internally generated funding, increases dependence on financing or partners, and leaves earnings highly sensitive to trial spending.
Persistent Cash BurnSustained negative operating and free cash flow indicates that clinical development continues to consume substantial cash without self-funding operations. The deterioration in free cash flow raises the likelihood that additional capital or collaboration proceeds will be needed to maintain the pipeline.
Shrinking Equity BaseThe substantial decline in shareholders’ equity reflects the cumulative effect of ongoing losses and reduced capital backing for future development. A smaller equity base can constrain financial resilience and may increase reliance on external funding, with dilution risk for shareholders.
Immutep News
YP1A FAQ
What was Immutep’s price range in the past 12 months?
Immutep lowest stock price was €0.24 and its highest was €2.92 in the past 12 months.
What is Immutep’s market cap?
Immutep’s market cap is €42.77M.
When is Immutep’s upcoming earnings report date?
Immutep’s upcoming earnings report date is Feb 25, 2027 which is in 162 days.
How were Immutep’s earnings last quarter?
Immutep released its earnings results on Sep 02, 2026. The company reported -€0.145 earnings per share for the quarter, missing the consensus estimate of -€0.023 by -€0.122.
Is Immutep overvalued?
According to Wall Street analysts Immutep’s price is currently Undervalued.
Does Immutep pay dividends?
Immutep does not currently pay dividends.
What is Immutep’s EPS estimate?
Immutep’s EPS estimate is -0.05.
How many shares outstanding does Immutep have?
Immutep has 147,372,130 shares outstanding.
What happened to Immutep’s price movement after its last earnings report?
Immutep reported an EPS of -€0.145 in its last earnings report, missing expectations of -€0.023. Following the earnings report the stock price went up 1.351%.
Which hedge fund is a major shareholder of Immutep?
Currently, no hedge funds are holding shares in DE:YP1A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immutep Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€1.30 (319.58% Upside)
€1.30 (319.58% Upside)
Blogger Sentiment
Bullish
DE:YP1A Sentiment 100%
Sector Average 62%
Sector Average 62%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.92%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-43.93%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Immutep
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
YP1A Stock 12 Month Forecast
Average Price Target
€1.30
▲(319.58% Upside)
Technical Analysis
Cellectis SA
―
Cartesian Therapeutics
―
―
Silence Therapeutics
―
Lyell Immunopharma
―